Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cediranib
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
gemcitabine + cediranib is an investigational chemotherapy–targeted therapy combination in which gemcitabine, a nucleoside analog that inhibits DNA synthesis and induces apoptosis in proliferating cells, is paired with cediranib, an oral small‑molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3) with additional activity against platelet-derived growth factor receptors and c-KIT, to enhance antitumor efficacy through simultaneous cytotoxic and anti‑angiogenic mechanisms in solid tumors such as biliary tract cancer and non-small cell lung cancer.
02
Targets
RRM1KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAPDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on gemcitabine + cediranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cediranib.